Pharma Mar . Edison Investment Publica Nuevo Informe y Nuevo Precio Objetivo de 7,56 euros .

...

Pharma Mar , valor a tener muy en cuenta por análisis técnico .

César Nuez // Bolsamania | 19 jul, 2017 .

Pharmamar es uno de los valores que no perderemos de vista en las próximas sesiones a la espera de la aparición de una señal de fortaleza que nos haga pensar en una toma de posiciones.

La tendencia de la compañía a medio y largo plazo es claramente alcista si bien en el corto plazo estaremos muy pendientes de un cierre por encima de los 4,06 euros lo que nos haría pensar en el final de la consolidación de las últimas semanas y en el comienzo de un nuevo tramo alcista .
...

Zepsyre BRCA2 Patients . An Upcoming Conversation With An Expert - Discussing The BRCA Mutation Research Landscape: Lurbinectedin And Its Potential In BRCA2 Patients.

An Upcoming Conversation With An Expert - Discussing The BRCA Mutation Research Landscape: Lurbinectedin And Its Potential In BRCA2 Patients.

Jul. 18, 2017 8:16 AM

Wednesday 7-18, at 10:30am ET PharmaMar is Sponsoring an Expert Interview on Lurbinectedin and BRCA2 mutations with Slingshot Insights. With PharmaMar’s stock up over 45% in 2017 and multiple Phase 3 programs underway for Lurbinectedin, investor interest in the story has picked up this year.

This call will be an interview with Dr. Pamela Munster, a respected Oncologist and Key Opinion Leader. Dr. Munter is the Co-Director of the UCSF BRCA Research Center and Principal Investigator of many early oncology studies.

Why Investors Should Care:

Dr. Munster is a leading expert on BRCA research and involved in many early stage trials.

• The conversation will focus not just on PharmaMar’s Lurbinectedin, but DNA repair as a mechanism and where this approach could fit in a treatment landscape with approved PARP inhibitors.
• The call will examine the nuances of the public data for Lurbinectedin and give investors a deep dive into the basic science basis for the approach .

...

Zepsyre and Yondelis Effective in BRCA2-Associated Metastatic Breast Cancer .

Published Online: July 18, 2017

AJMC Staff

AN INTERIM ANALYSIS OF TWO phase 2 trials has found that trabectedin and lurinectedin demonstrated remarkable activity as single agents in BRCA2-associated metastatic breast cancer, with 33% clinical response with trabectedin and 61% with lurbinectedin. 

Results of the analysis were reported in a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

...